WO2000006189A3 - Conversion de quinones naturelles en derives de quinones au moyen du facteur d'inhibition de migration de macrophages et procedes d'utilisation correspondants - Google Patents

Conversion de quinones naturelles en derives de quinones au moyen du facteur d'inhibition de migration de macrophages et procedes d'utilisation correspondants Download PDF

Info

Publication number
WO2000006189A3
WO2000006189A3 PCT/US1999/017057 US9917057W WO0006189A3 WO 2000006189 A3 WO2000006189 A3 WO 2000006189A3 US 9917057 W US9917057 W US 9917057W WO 0006189 A3 WO0006189 A3 WO 0006189A3
Authority
WO
WIPO (PCT)
Prior art keywords
naturally
quinone
conversion
macrophage migration
occurring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/017057
Other languages
English (en)
Other versions
WO2000006189A2 (fr
Inventor
Graeme J Wistow
Vincent J Hearing
Francisco Solano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Priority to AU53226/99A priority Critical patent/AU5322699A/en
Publication of WO2000006189A2 publication Critical patent/WO2000006189A2/fr
Publication of WO2000006189A3 publication Critical patent/WO2000006189A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des procédés d'utilisation d'une protéine de la famille des facteurs inhibiteurs de migration de macrophages visant à favoriser la transformation d'une quinone naturelle toxique en un dérivé de quinone moins toxique, ce qui permet de détoxifier la quinone naturelle et d'empêcher la mort cellulaire. La présente invention concerne également des procédés de diagnostic, de prévention et de traitement de troubles dégénératifs caractérisés par la mort cellulaire provoquée par des quinones.
PCT/US1999/017057 1998-07-27 1999-07-27 Conversion de quinones naturelles en derives de quinones au moyen du facteur d'inhibition de migration de macrophages et procedes d'utilisation correspondants Ceased WO2000006189A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU53226/99A AU5322699A (en) 1998-07-27 1999-07-27 Conversion of naturally-occurring quinones to quinone derivatives by macrophage migration inhibition factor and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9424698P 1998-07-27 1998-07-27
US60/094,246 1998-07-27

Publications (2)

Publication Number Publication Date
WO2000006189A2 WO2000006189A2 (fr) 2000-02-10
WO2000006189A3 true WO2000006189A3 (fr) 2000-05-11

Family

ID=22244002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017057 Ceased WO2000006189A2 (fr) 1998-07-27 1999-07-27 Conversion de quinones naturelles en derives de quinones au moyen du facteur d'inhibition de migration de macrophages et procedes d'utilisation correspondants

Country Status (2)

Country Link
AU (1) AU5322699A (fr)
WO (1) WO2000006189A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015242A2 (fr) * 1994-11-16 1996-05-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procedes d'inhibition de la proliferation cellulaire par inhibition de l'activite mitogene du facteur inhibiteur de la migration des macrophages
WO1998009984A1 (fr) * 1996-09-03 1998-03-12 Yeda Research And Development Co., Ltd. Facteur d'immunisation privilegiee derive du systeme nerveux central et ses utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015242A2 (fr) * 1994-11-16 1996-05-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procedes d'inhibition de la proliferation cellulaire par inhibition de l'activite mitogene du facteur inhibiteur de la migration des macrophages
WO1998009984A1 (fr) * 1996-09-03 1998-03-12 Yeda Research And Development Co., Ltd. Facteur d'immunisation privilegiee derive du systeme nerveux central et ses utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MATSUNAGA J ET AL: "Enzyme activity of macrophage migration inhibitory factor toward oxidized catecholamines.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1999 FEB 5) 274 (6) 3268-71., XP002127443 *
SUZUKI M ET AL: "Substrate specificity for isomerase activity of macrophage migration inhibitory factor and its inhibition by indole derivatives.", JOURNAL OF BIOCHEMISTRY, (1997 NOV) 122 (5) 1040-5., XP002127442 *

Also Published As

Publication number Publication date
AU5322699A (en) 2000-02-21
WO2000006189A2 (fr) 2000-02-10

Similar Documents

Publication Publication Date Title
AU3920900A (en) Compounds and methods to treat cardiac failure and other disorders
CA2207333A1 (fr) Utilisation de nebivolol comme agent anti-atherogene
EP1266658A3 (fr) Utilisation de dérivés de l'acide bétulinique pour le traitement et la prévention du mélanome
WO2000035919A3 (fr) Composes
ZA200110504B (en) Dietary or pharmaceutical compositions for use for the prevention or treatment of hyperoxaluria.
CA2348735A1 (fr) Inhibiteurs heterocycliques de canaux potassiques
CA2199844A1 (fr) Composition pour le traitement d'affections de la peau
MY110104A (en) Saccharin derivative proteolytic enzyme inhibitors
EP0846466A3 (fr) Compositions pour le traitement de maladies arthritiques rhumatoides
CA2252515A1 (fr) Preparations pharmaceutiques pour la prevention et le traitement de troubles du systeme nerveux central
WO2000015205A3 (fr) Utilisation d'inhibiteurs acetylcholinesterases pour la preparation de compositions pharmaceutiques destinees au traitement de syndromes de douleur fonctionnelle et/ou organique
CA2315227A1 (fr) Arylpiperazines pour lutter contre le recepteur 1a de la serotonine
AU2001284413A1 (en) Medicinal compositions for preventing or treating heart failure
WO2000001668A3 (fr) INHIBITEURS DE NAALADase UTILES COMME COMPOSES ET COMPOSITIONS PHARMACEUTIQUES
BG105197A (en) Polymorph form of a medicament
WO2001030335A3 (fr) Compositions pharmaceutiques utiles dans la prevention et le traitement d'une maladie induite par la proteine beta-amyloide
WO2001034596A3 (fr) DERIVES DE PYRROLECARBONYLIMINO UTILISES COMME INHIBITEURS DE LA NAALADase
AU4376396A (en) Use of andrographolide compounds to treat or prevent pathogenicity of diseases
WO1999024026A3 (fr) Methode de traitement des troubles lies a l'apoptose au moyen de composes de glyoxylamide n-heterocycliques
AU4414999A (en) Inhibition of delta-9-desaturase activity by saponins
WO2000029012A3 (fr) Procedes servant a soulager les symptomes du cancer
AU4142999A (en) Topical pharmaceutical compositions useful for the treatment of cutaneous or circulatory pathologies on inflammatory, immune, proliferative or degenerative basis
WO1999014234A3 (fr) Stimulation ou inhibition de l'angiogenese et de la cardiovascularisation
WO1992004359A3 (fr) Monosaccharides presentant une activite anti-proliferative et anti-inflammatoire, compositions et leurs utilisations
AU2843995A (en) Preventive or alleviating agent for medical symptoms caused by delayed allergy reactions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase